Colgate-Palmolive Company $CL Stock Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. lifted its holdings in shares of Colgate-Palmolive Company (NYSE:CL – Free Report) by 18.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,651,979 shares of the company’s stock after purchasing an additional 251,887 shares during the period. Russell Investments Group Ltd. owned about 0.21% of Colgate-Palmolive worth $141,843,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. State Street Corp boosted its position in Colgate-Palmolive by 97.4% during the second quarter. State Street Corp now owns 94,195,992 shares of the company’s stock valued at $8,635,889,000 after buying an additional 46,476,510 shares during the period. Bank of America Corp DE purchased a new position in shares of Colgate-Palmolive in the second quarter worth about $567,483,000. Envestnet Asset Management Inc. lifted its stake in shares of Colgate-Palmolive by 266.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 4,146,337 shares of the company’s stock valued at $380,136,000 after acquiring an additional 3,014,860 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Colgate-Palmolive by 151.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 4,276,774 shares of the company’s stock valued at $364,894,000 after acquiring an additional 2,575,530 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of Colgate-Palmolive by 5,949.4% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,927,630 shares of the company’s stock valued at $164,292,000 after acquiring an additional 1,895,765 shares during the last quarter. Hedge funds and other institutional investors own 80.41% of the company’s stock.

Colgate-Palmolive Stock Down 0.1%

NYSE:CL opened at $99.62 on Monday. The company has a debt-to-equity ratio of 11.23, a current ratio of 0.96 and a quick ratio of 0.63. The firm’s 50-day moving average price is $90.94 and its 200-day moving average price is $90.29. The company has a market capitalization of $79.19 billion, a PE ratio of 39.07, a P/E/G ratio of 4.51 and a beta of 0.31. Colgate-Palmolive Company has a 1-year low of $75.96 and a 1-year high of $101.18.

Colgate-Palmolive (NYSE:CL – Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Colgate-Palmolive had a net margin of 9.65% and a return on equity of 607.88%. The company had revenue of $5.37 billion during the quarter, compared to analysts’ expectations of $5.34 billion. During the same period last year, the company posted $0.91 EPS. Colgate-Palmolive’s revenue was up 4.6% on a year-over-year basis. On average, equities analysts predict that Colgate-Palmolive Company will post 3.92 EPS for the current fiscal year.

Colgate-Palmolive Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, November 13th. Shareholders of record on Tuesday, October 20th were issued a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Tuesday, October 20th. Colgate-Palmolive’s payout ratio is 83.14%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on CL shares. Barclays raised their price target on Colgate-Palmolive from $87.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 3rd. Bank of America boosted their price objective on Colgate-Palmolive from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Monday, November 2nd. Jefferies Financial Group restated a “hold” rating and issued a $89.00 target price (up from $88.00) on shares of Colgate-Palmolive in a report on Monday, August 3rd. Piper Sandler decreased their target price on shares of Colgate-Palmolive from $98.00 to $95.00 and set an “overweight” rating on the stock in a research note on Monday, September 21st. Finally, BNP Paribas Exane reaffirmed an “outperform” rating and set a $108.00 price target (up from $97.00) on shares of Colgate-Palmolive in a research report on Monday, November 2nd. Thirteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $101.22.

Read Our Latest Research Report on CL

Insider Buying and Selling

In other news, COO Panagiotis Tsourapas sold 19,938 shares of the stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $98.74, for a total value of $1,968,678.12. Following the sale, the chief operating officer directly owned 9,111 shares of the company’s stock, valued at approximately $899,620.14. This represents a 68.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Gregory Malcolm sold 4,100 shares of the firm’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $97.97, for a total value of $401,677.00. Following the transaction, the executive vice president owned 10,061 shares of the company’s stock, valued at $985,676.17. The trade was a 28.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 77,414 shares of company stock valued at $7,613,786. Insiders own 0.43% of the company’s stock.

Trending Headlines about Colgate-Palmolive

These are some of the CL headlines that stood out recently:

  • Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $3.91 from $3.85, close to the $3.92 consensus, and nudged its FY2027 and FY2028 forecasts higher to $4.06 and $4.38, respectively. These revisions suggest modest confidence in longer-term earnings growth. Zacks Research Has Bullish Forecast for CL FY2026 Earnings
  • Neutral Sentiment: A comparison with Kimberly-Clark highlighted Colgate-Palmolive’s leading global oral-care position and its pet-nutrition business as potential growth diversifiers, but the article did not report a new company-specific catalyst. Colgate-Palmolive vs. Kimberly-Clark
  • Negative Sentiment: A Colgate-Palmolive executive vice president sold $401,677 worth of company shares. Insider sales can weigh on sentiment, although a single transaction does not necessarily indicate a change in the company’s outlook. Insider Selling: Colgate-Palmolive EVP Sells Stock

About Colgate-Palmolive

(Free Report)

Colgate-Palmolive is a global consumer products company whose business spans oral care, personal care, home care and pet nutrition. Its products include toothpaste, toothbrushes, mouthwashes, soaps, shampoos, cleaning products and pet food. The company’s best-known brands include Colgate, Palmolive, elmex, Softsoap, Ajax and Hill’s Pet Nutrition. It sells products through retail and other channels in markets around the world. Founded in 1806 by William Colgate as a soap and candle business in New York City, the company has grown into an international manufacturer of household and personal care products.

Featured Articles

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive Company (NYSE:CL – Free Report).

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.